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1. Introduction 
The immune system of higher organisms has the unique capability of mounting a specific 
and adaptive response against invading pathogens. Specific in the sense that immune cells 
recognize molecular features from foreign pathogens, and adaptive in the sense that upon re-
encounter of the foreign pathogen the immune system respond faster and more efficiently, 
which is the basic principle used in vaccination. In addition, the immune system has 
evolved the innate capability of recognizing common, slow mutating features on pathogens 
by using several different pattern recognition receptors. These defense mechanisms are 
important, but just like any other organisms pathogens also mutate to adapt to selection 
pressures thereby escaping immune surveillance. Likewise, the immune system of higher 
organisms is not a static system, but rather a dynamic ever-changing defense system 
continuously evolving over millions of years to constantly battle pathogens trying to 
overcome immune defense barriers and take over the host protein translation machinery. 
Furthermore, the immune system needs to be in balance with its host, but sometimes the 
line between functional immunity and auto-reactivity becomes hard to draw. Importantly, it 
is now a firmly established concept that the immune system eradicates host cells undergoing 
malignant transformation to prevent tumor formation. With these functions in mind, it is 
reasonable to claim the adaptive immune system as highly essential in the protection of 
pathogenic infections and malignant cells. The adaptive immune system contains a variety 
of T cells; two major groups are the CD4+ T cells that interact with MHC class II (MHC-II) 
cell surface receptors, and CD8+ T cells, also termed cytotoxic T cells (CTLs) that interact with 
MHC class I (MHC-I) cell surface receptors. The CTLs kill malignant host cells or host cells 
infected with foreign pathogens. This chapter focuses on the immunology concerning CTLs 
and MHC-I. Specifically, we focus on the multi-step, intracellular maturation of MHC-I. 
CTLs continuously re-circulate throughout our body and secondary lymphoid organs to 
scan our cells for peptides presented on MHC-I. These peptides are derived from the 
interior of the cell, and presented on MHC-I outside the cell on its membrane surface. Each 
MHC-I receptor binds and presents one small endogenous or foreign peptide, which is 
derived from within the cell, (Roder, Geironson et al. 2008) and the entire ligand-receptor 
complex is termed a peptide-MHC-I complex (pMHC-I). Essentially, through their T cell 
receptor (TcR) the CTLs may recognize a particular pMHC-I on the cell surface of the 
presenting cell. The strength and outcome of this recognition depends on the identity of 
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both the TcR and the pMHC-I, and occurs normally only when a foreign peptide is bound in 
the pMHC-I. This is the exact purpose of MHC-I defense system: use peptides to report any 
intracellular abnormalities such as infections or malignant states, and make the CTLs kill 
these cells. In the secondary lymphoid organs naïve CTLs encounter the pMHC-I complexes 
presented by professional APCs, cells with unique co-stimulatory capability able to prime 
naïve T cells. Upon recognition of a pMHC-I complex the CTLs become active dividing cells 
able to kill infected cells outside the lymphoid organs (Santana and Esquivel-Guadarrama 
2006). An important characteristic of CTL activity is that it is pMHC-I restricted, giving that 
it only recognizes the peptide antigen in the context of a certain MHC-I molecule. Also, the 
pMHC-I is only recognized if it reaches and remains on the cell surface of the APC. If the 
pMHC-I disintegrates along the maturation and transport to, or while staying at, the cell 
surface it will never be available for CTL scrutiny. These criteria impose serious 
requirements to the intricate MHC-I maturation processes inside the cell as we shall describe 
in this chapter. 
2. The mature MHC-I binds only certain peptides in its binding groove 
Before we delve deep into the MHC-I maturation in the cell, we first introduce the reader to 
the final product – the mature pMHC-I complex and some of its important properties. 
MHC-I molecules are found on most nucleated cells in the body. The MHC-I in humans is 
called human leukocyte antigen class I (HLA-I) and is grouped into A, B and C based on the 
genetic locus. Because the protein products, the allomorphs, of the alleles occupying the 
HLA-A, -B and -C loci are all co-dominantly expressed and chromosomes exist in pairs, one 
from the paternal and one from the maternal side, usually six different allomorphs are 
expressed in each human. To date (2011), over 5,000 different alleles and over 3,000 different 
allomorphs have been identified and sequence information is freely available from the HLA 
Informatics Group (http://www.anthonynolan.com/HIG/data.html). As seen in figure 1 
the final pMHC-I complex consists of a MHC-I heavy chain (HC) that is folded into three -
domains; the 1- and 2-domains are intertwined making up the membrane distal peptide 
binding groove, whereas the membrane proximal 3-domain has an Ig-like structure that 
supports binding of the MHC-I light chain, 2-microglobulin (2m). In addition, 2m 
stabilizes from below the anti-parallel -sheets and helices allowing these structural 
elements to create a large, but tight, peptide binding groove containing six peptide amino 
acid binding pockets. 
These pockets are very important in determining the peptide binding specificity of any 
particular MHC-I allomorph. The MHC-I residues in each binding pocket determine, which 
peptide residues are compatible enough to bind in the pocket, and thus determine the 
requirement for particular residues at particular positions in the binding peptide. This is the 
MHC-I peptide binding specificity, and it turns out that only a few residue positions in the 
peptide are the major determinants of peptide binding specificity. Thus, only a small 
fraction of the entire peptide universe will be allowed to bind to any particular MHC-I 
allomorph, and it is this knowledge that is one important key to allow us to design peptide-
based vaccines that are highly specific, cheap and easy to disseminate. In this respect, it is 
important to understand MHC-I maturation and the underlying criteria. 
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Fig. 1. The MHC-I protein structure allows short peptides to bind tightly in the peptide 
binding groove spanning the MHC-I 1/2-domains. A) Schematic structure of MHC-I, 
which consists of a HC with 3 -domains (light blue) and 2m (dark blue). In the peptide 
binding groove (at the top) the MHC-I has bound a peptide (yellow). B)  The protein crystal 
structure of HLA-B*15:01. The HC is colored light grey and 2m is colored dark grey. The 
peptide binding groove is located at the top between two encapsulating -helices (red). The 
peptide (yellow) is seen from the C-terminal. The electron density of the Cys101-Cys164 
disulfide bond in the peptide binding groove is shown in the inset. C) Top down view of the 
MHC-I peptide binding groove. D) The electron density of the peptide (LEKARGSTY). 
Shown from the 2-helix the peptide N-terminal is at the left. 
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3. MHC-I matures and is loaded with peptide inside the cell 
The maturation of MHC-I and ultimate generation of pMHC-I complexes initially involves 
two different processes that later merge into one common maturation process. Firstly, the 
HC and 2m have to be produced separately and translocated into the endoplasmic 
reticulum (ER). At the same time, the peptide that will later bind to the MHC-I has to be 
produced and transported into the lumen of the ER. The entire MHC-I antigen processing 
machinery (APM) process is illustrated in figure 2 showing the accessory proteins and 
chaperones involved in the stepwise processes ultimately resulting in a fully mature pMHC-
I complex that is exported to and situated on the cell surface. 
Several APM components are involved in the MHC-I quality control cycle, and regulates the 
sequential maturation process of MHC-I (Paulsson and Wang 2004). The HC undergoes co-
translational glycosylation while being translocated into the ER lumen in a nascent unfolded 
state. Inside the ER the HC instantly interacts with BiP, the Hsp90 protein, and soon also 
with calnexin, a general ER lectin chaperone. Calnexin binds to newly synthesized proteins 
with mono-glycosylated N-linked glycans, and in line with this also to early folding stages 
of the N-glycosylated HC (Ware, Vassilakos et al. 1995). This initial chaperoning of the HC  
prevents it from collapse and aggregation, and also sets the HC in a conformation that 
allows mature 2m to bind the HC forming the MHC-I heterodimer. Calnexin interacts with 
ERp57, a member of the protein disulfide isomerase (PDI) family, and is thought to involve 
in the correct formation of disulfide bonds within the HC (Oliver, Roderick et al. 1999). 
These intramolecular disulfide bonds strengthen the structural integrity and stability of the 
final pMHC-I complex. The newly formed MHC-I heterodimer is inherently unstable, but 
might be partly stabilized by binding a suboptimal peptide that later dissociates from the 
MHC-I. During these maturation steps calnexin dissociates from MHC-I and is immediately 
replaced by calreticulin, its soluble homologue. 
At this stage the MHC-I might not be further matured due to the following reasons: 1) The 
MHC-I has acquired a peptide that induces final MHC-I maturation, 2) the particular MHC-I 
allomorph is inherently less prone to, or binds a peptide not inducing full maturation but 
inducing a structure not able to integrate into the peptide-loading complex (PLC), or 3), the 
MHC-I integration into the PLC is prohibited by viral interference (Roder, Geironson et al. 
2008). However, for most HLA-I allomorphs the majority of MHC-I molecules are integrated 
into the PLC through binding to tapasin, where the late-stage maturation of the pMHC-I 
complex takes place. Tapasin has been ascribed many functions besides integrating MHC-I 
into the PLC. One of the most important functions, but also difficult to study, is to edit – and 
thereby optimize – the peptide loaded onto the MHC-I in the PLC with the purpose of 
generating stable pMHC-I complexes. In the PLC, which at least consists of the transporter 
associated with antigen processing (TAP), tapasin, calreticulin and ERp57, the MHC-I finally 
matures into a stable pMHC-I complex. ERp57 has proven important in the PLC, because it 
forms a disulfide conjugate with tapasin (Peaper, Wearsch et al. 2005). The tapasin-ERp57 
disulfide conjugate has been suggested to significantly boost the efficiency, whereby tapasin 
edits the MHC-I bound peptide repertoire (Wearsch and Cresswell 2007). 
So far, we have discussed the production and initial folding of the MHC-I. The generation 
and supply of peptides is equally important in the maturation of the final pMHC-I complex, 
and it all starts in the cytosol. Here, proteins are produced by the ribosome, but sometimes 
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the production fails, resulting in defective ribosomal products (DRiPs). The DRiPs are 
targeted for degradation by the cytosolic proteasome, and it is from this cleavage process that 
peptides are generated. It has been proposed that a large fraction of the MHC-I binding 
peptides derive from DRiPs (Yewdell, Anton et al. 1996). Other cytosolic proteases, such as 
TPPII, may assist in trimming the proteasome processed peptides.  
 
Fig. 2. An array of APM components present in the ER and the cytosol is involved in the 
sequential maturation and peptide loading of MHC-I. Early folding stages of MHC-I are 
promoted by BiP and then calnexin, which recruits ERp57. Subsequently, the MHC-I HC 
associates with 2m, and calnexin is replaced by calreticulin. Most of the MHC-I molecules 
are recruited into the PLC, which consists of ERp57, calreticulin, tapasin and TAP, where the 
folding of the mature MHC-I conformation as well as peptide loading is facilitated. Peptides 
are generated in the cytosol by the proteasome and trimmed in the ER to MHC-I optimal 
lengths by ERAP1. MHC-I molecules loaded with optimal peptides become stable and can 
exit the ER and be transported via the Golgi network to the cell surface, possibly, between 
ER and Golgi, through transport in COP-II vesicles. Loading of an optimal peptide can also 
occur before recruitment into PLC. The stable pMHC-I complex can the exit the ER through 
alternative ER exit sites for transport to the cell surface. Sub-optimally loaded MHC-I 
molecules can escape the ER but are the recycled in COP-I vesicles recruited by tapasin, 
which recycles the MHC-I molecule back to the ER for optimal loading. 
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An essential part of the PLC is the heterodimeric TAP, which is composed of the TAP1 and 
TAP2 subunits, both containing an N-terminal transmembrane domain and a C-terminal 
cytosolic nucleotide-binding domain. Situated in the ER membrane TAP actively 
translocates the cytosolic peptides into the ER in a multistep process, which begins with 
association of peptides, usually 8-16 amino acid long with TAP (van Endert, Tampe et al. 
1994). Peptide binding to TAP is followed by an isomerization of the TAP complex that 
triggers an ATP-dependent peptide translocation across the ER membrane (Neefjes, 
Momburg et al. 1993). Many of the peptides that are transported by TAP into the ER lumen 
are still too long to bind firmly in the MHC-I peptide binding groove. These peptides are 
then further trimmed by the ER aminopeptidases ERAP1 and ERAP2 at the extended N-
terminus to 8-10 amino acids, which is the appropriate length for association with MHC-I 
(York, Chang et al. 2002; Tanioka, Hattori et al. 2003).  
We define an optimal MHC-I binding peptide as a peptide binding to MHC-I resulting in a 
stable pMHC-I complex. Thus, as a general rule, an optimal peptide has to bind firmly in the 
MHC-I peptide binding pockets. When a stable pMHC-I is formed, it is released from the 
PLC and transported to the cell surface. This underscores the importance of PLC-mediated 
pMHC-I quality control. pMHC-I complexes that consists only of suboptimal peptides are 
(per definition) unstable, and are not released from the PLC. This ensures the release of only 
stable pMHC-I complexes to the cell surface, which is vital for the subsequent CTL scrutiny. 
The pMHC-I transportation to the cell surface has been suggested to start with packaging of 
the pMHC-I complexes in COPII vesicles, which then migrate to the Golgi apparatus, and 
then further on to the cell surface (Paquet, Cohen-Doyle et al. 2004). The following sections 
discuss the MHC-I maturation, and peptide supply in much more detail. 
4. The MHC-I maturation is facilitated by multi-protein complexes in the ER 
In this section we go through the details of the HC production and folding in the ER 
involving APM components such as calnexin, calreticulin, ERp57 and tapasin. The 
chaperone BiP, known to interact cotranslationally with the nascent HC before other 
chaperones will not be further discussed. The following interactions of HC with each APM 
component are discussed in the maturation sequence as it is thought to occur. 
4.1 Calnexin and calreticulin shape the initial MHC-I heterodimer 
Both calnexin and its soluble homologue calreticulin are part of the general ER protein 
folding machinery, and bind to mono-glucosylated proteins. Despite overlapping substrate 
specificities, they also have distinct preferences, which can be explained by: 1) the positions 
and numbers of the glycosylation sites on the target protein (High, Lecomte et al. 2000), and 
2) the membrane anchoring of calnexin versus the soluble calreticulin. The latter was shown 
to be a major determinant, since an experiment with soluble calnexin demonstrated that the 
glycoprotein association pattern for soluble calnexin resembles the pattern for calreticulin 
(Danilczyk, Cohen-Doyle et al. 2000). Similarly, calreticulin expressed with an ER membrane 
anchor binds to a set of glycoproteins resembling those proteins normally bound to calnexin 
(Wada, Imai et al. 1995).  
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4.1.1 Calnexin and calreticulin bind differently to MHC-I around the glycosylation site 
As alluded to in the previous section, the location of the glycosylation sequon in the MHC-I 
determines its binding to calnexin and calreticulin, which would then be reflected in the 
sequential maturation of MHC-I. Human MHC-I HCs have a single N-linked glycosylation 
site at Asn86, whereas mouse HC possess glycosylation sequons at additional sites (Maloy 
1987). To support this notion, experiments have shown that introduction of a second 
glycosylation site in the human HC at the same position as in mouse HC, resulted in a 
maturation process that more resembled the mouse HCs with respect to calnexin and 
calreticulin association (Zhang and Salter 1998). In the human, the HC glycosylation sequon 
is located close to the ER membrane during translocation into the ER, calnexin first gains 
access to this site. Calnexin induces 2m binding to the HC, which brings the glycosylation 
sequon away from the membrane allowing the soluble calreticulin to replace calnexin 
(Solheim, Carreno et al. 1997).  
In the 2m deficient human cell line Daudi, there is little or no association of MHC-I HC 
with calreticulin, suggesting that calreticulin only binds the MHC-I heterodimer, but not the 
single HC (Solheim, Harris et al. 1997; Tector, Zhang et al. 1997). In mice the situation is 
somewhat different, because calnexin not only binds to free HC but also to the HC 
heterodimer (Nossner and Parham 1995). Furthermore, it was shown that calnexin is 
associated with assembled mouse MHC-I even after peptide loading and dissociation from 
the PLC (Suh, Mitchell et al. 1996). Mouse HCs are able to bind to TAP also in the 2m 
deficient mouse cell line S3, and calnexin is present in this complex. Interestingly, also the 
fully folded human HLA-B*27 heterodimer has been shown to bind calnexin in human cells 
when using sensitive experimental systems, this is however outside the PLC (Carreno, 
Solheim et al. 1995). This shows, that the calnexin and calreticulin binding to MHC-I is not 
only species specific but also HC allomorph specific. 
4.1.2 Glycosylation and the calnexin/calreticulin cycle 
During the folding process, the MHC-I go through several rounds of dynamic binding, 
release and re-binding of calnexin/calreticulin in what is referred to the glycoprotein 
quality-control cycle (Helenius and Aebi 2004). The cycle is part of the general protein 
folding machinery in the ER, and is here illustrated in figure 3 in the context of MHC-I 
maturation. When bound calnexin or calreticulin is released from the HC, its glycosyl 
moiety becomes available for de-glucosylation by glucosidase II. Subsequently, the MHC-I 
folding status is evaluated by the soluble enzyme UDP-glucose glycosyl transferase 
(UGGT). If MHC-I is incorrectly folded the HC will be re-glycosylated and re-enter the 
glycoprotein quality control cycle (Helenius and Aebi 2004).  
During translation and the BiP assisted folding the Asn86 of the MHC-I HC is N-glycosylated 
resulting in attachment of a Glc3Man9GlcNAc2 oligosaccharide moiety (Kornfeld and Kornfeld 
1985). The two outer glucose residues are then removed by glycosidase I and II leaving the 
MHC-I HC mono-glucosylated (Glc1Man9GlcNAc2) at this step in the maturation process 
(Elbein 1991). This enables subsequent interaction of HC with the lectin chaperones, calnexin 
and calreticulin (Hebert, Foellmer et al. 1995; Ware, Vassilakos et al. 1995). 
Both calnexin and calreticulin bind mono-glucosylated substrates (Hammond, Braakman  
et al. 1994; Peterson, Ora et al. 1995). In addition they both interact with unfolded  
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Fig. 3. The glycoprotein quality control cycle. Following the cotranslational glycosylation of 
MHC-I during translocation into the ER, glucosidase I and II remove the two outer glucoses 
immediately. When calnexin/calreticulin releases MHC-I the third glucose is removed and 
the folding status is evaluated by UDP-glucose glycosyl transferase. Incorrectly folded 
proteins will be re-glycosylated and re-enter the glycoprotein quality cycle whereas terminally 
misfolded proteins are degraded in the ER associated degradation (ERAD) pathway. 
non-glucosylated proteins (Ihara, Cohen-Doyle et al. 1999; Saito, Ihara et al. 1999). As the 
newly synthesized MHC-I HC enters the ER via the translocon it is subjected to N-linked 
glycosylation of the sequon Asn-X-Ser/Thr (Bause, Muller et al. 1983). The glycosylation 
adds three glucose residues to the protein. The presence of a glycosylation site within the 
first 50 amino acids of a protein entering the ER through the translocon allows the 
interaction with calnexin and calreticulin to begin cotranslationally (Molinari and Helenius 
2000). Inhibition of glycosylation results in many cases in misfolded, aggregated and 
dysfunctional proteins (Hickman, Kulczycki et al. 1977; Konig, Ashwell et al. 1988; Williams 
and Enns 1991). After trimming by glucosidase I and glucosidase II, mono-glucosylated HC 
is generated (Parodi 2000). The mono-glucosylated HC will then bind to calnexin for 
oxidative folding (Nossner and Parham 1995). Sequentially, the immature HC will create a 
heterodimer with the stabilising polypeptide く2m. As this occurs, calnexin is replaced by 
calreticulin, which then recruits the immature heterodimer into the PLC where it can be 
loaded with high affinity peptides (Wearsch, Peaper et al. 2011).  
It has been shown that the glycosylation of the MHC-I molecules in the ER is highly 
regulated. Nearly all monoglycosylated HC found in human cells are incorporated into the 
PLC and if deglycosylation is inhibited, their interaction with the PLC is significantly 
prolonged (Radcliffe, Diedrich et al. 2002; Wearsch, Peaper et al. 2011). A study using in vitro 
methods showed that glucosidase II could only trim free monyglycosylated HC and not 
those that were bound to the PLC (Wearsch, Peaper et al. 2011). This indicates that the 
glucose residues of the monoglycosylated MHC-I molecule become accessible to the 
glucosidase II first after its release from the PLC. After the last glucose residues has been 
removed, the MHC-I molecule can no longer associate with the PLC as its recruitment is 
dependent on the interaction with calreticulin which only binds to monoglycosylated 
proteins (Wearsch, Peaper et al. 2011). However, it has been proposed that if a 
deglycosylated MHC-I molecule is loaded with suboptimal peptide it can be rescued back 
into the PLC via the soluble enzyme UDP-glucose glycoprotein glucosyltransferase 1 
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(UGT1) (Zhang, Wearsch et al. 2011). The UGT1 can selectively reglycosylate the 
suboptimally loaded/incorrectly folded MHC-I molecule, and after trimming by 
glucosidase I and glucosidase II the monoglycosylated MHC-I molecule can ones again 
enter the PLC, this what is called the calnexin/calreticulin cycle. After the MHC-I molecule 
has become correctly folded and loaded with an optimal peptide it will be deglycosylated 
and released from the calnexin/calreticulin cycle for transport from the ER to the cell 
surface for presentation (Radcliffe, Diedrich et al. 2002). The time spent in the calnexin-
calreticulin cycle can range from a few minutes to several hours, the more complex the 
folding of a protein, the more time it needs to spend. If a protein fails to reach mature 
conformation it is destined for ERAD (Klausner and Sitia 1990). Also for degradation tags 
the trimming of N-linked glycans has been shown to be of importance and calnexin has been 
implicated in the sequestering of proteins tagged for degradation (Liu, Choudhury et al. 
1997). 
4.1.3 Lack of calreticulin, but not calnexin, diminishes MHC-I quality control 
In normal human cells the PLC consist of calreticulin, tapasin, ERp57, TAP, maturing MHC-
I (Sadasivan, Lehner et al. 1996; Peaper, Wearsch et al. 2005). Ten years ago the hypothesis 
was that the abundant ERp57 found in the PLC was a consequence of its interaction with 
calreticulin or possibly calnexin (Oliver, Roderick et al. 1999). However, co-
immunoprecipitation from K42 cells (a calreticulin deficient embryonic mouse fibroblast cell 
line) showed complexes of calnexin together with ERp57, tapasin and HC suggesting an 
alternative PLC constellation lacking calreticulin (Gao, Adhikari et al. 2002). Co-
immunoprecipitation in lysates of K42 cells showed that ERp57 was associated with TAP, 
but that no calnexin could be detected in these precipitates, suggesting that neither calnexin 
nor calreticulin are essential for recruitment of ERp57 to the PLC (Suh, Mitchell et al. 1996; 
Gao, Adhikari et al. 2002). More recently it has been shown that ERp57 is directly disulfide 
conjugated to tapasin in the PLC (Peaper, Wearsch et al. 2005). 
Calnexin deficient mice are viable and they show no discernible effects on other systems, 
including the immune system, possible because calreticulin effectively replaces the calnexin 
function even at the earlier MHC-I HC maturation stages. In contrast, calreticulin deficiency 
negatively impacts both trafficking and localization of MHC-I molecules. In the absence of 
calreticulin the MHC-I molecules are not retained in the ER, and the transport of immature 
MHC-I to the cell surface is accelerated. In K42 cells, many MHC-I molecules would be 
loaded with suboptimal peptides, due to lack of calreticulin in the MHC-I quality control, 
and the pMHC-I complexes would fall apart either before or on the cell surface (Gao, 
Adhikari et al. 2002). It was shown that the peptide-receptive MHC-I molecules were not 
found in the cis-Golgi or ER as they would be in wild type cells; instead they were found in 
endosomes and lysosomes. Under these circumstances the suboptimally loaded MHC-I 
molecules are transported to the cell surface, where the pMHC-I complexes almost instantly 
disintegrate, and are readily endocytosed ultimately leading to a significant reduction in 
MHC-I mediated antigen presentation (Howe, Garstka et al. 2009). 
4.2 ERp57 oxidizes the MHC-I heavy chain and supports tapasin function 
ERp57 is a multifunctional protein belonging to the thioredoxin family of proteins (Khanal 
and Nemere 2007). The protein structure is made up of four domains a, b, a’ and b’ (Ferrari 
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and Soling 1999; Silvennoinen, Myllyharju et al. 2004). ERp57 is mainly, but not exclusively, 
an ER resident protein (Turano, Coppari et al. 2002) with a C-terminal Gln-Glu-Asp-Leu 
(QEDL) retention signal (Urade, Oda et al. 1997) and two thioredoxin domains with CGHC 
motifs shared with ERp72, protein disulfide isomerase (PDI) and other members of the 
thioredoxin family. Not only have many names been designated to this protein but several 
different functions of ERp57 have also been suggested including thiol-dependent 
oxidoreductase (Bourdi, Demady et al. 1995; Hirano, Shibasaki et al. 1995), cysteine protease 
(Urade and Kito 1992; Urade, Nasu et al. 1992), carnitine palmitoyl transferase (Wada, Imai 
et al. 1995), a hormone induced protein of the brain (Mobbs, Fink et al. 1990; Mobbs, Fink et 
al. 1990) and in combination with calnexin and/or calreticulin as a chaperone for N-
glycosylated proteins in the ER (Oliver, van der Wal et al. 1997).  
In the ER, ERp57 has been shown to be associated with the PLC where it plays a critical role 
in the MHC-I maturation (Dong, Wearsch et al. 2009). It has also been shown to be involved 
in the quality control of other newly synthesized glycoproteins (Urade, Okudo et al. 2004; 
Khanal and Nemere 2007). In the PLC, ERp57 is covalently bound to tapasin via a disulfide 
bond between Cys95 of tapasin and Cys57 of ERp57, however the structural characterisation 
of the complex indicates that the heterodimer is also stabilised by non-covalent interactions 
between tapasin and the a and a’ domains of ERp57 (Dong, Wearsch et al. 2009). Calnexin 
and calreticulin, which both bind to ERp57 associate at the b and b’ domains of the protein 
(Russell, Ruddock et al. 2004; Kozlov, Maattanen et al. 2006). It has been suggested that the 
binding to calnexin and calreticulin is required for the recruitment of ERp57 into the PLC 
(Oliver, van der Wal et al. 1997; Oliver, Roderick et al. 1999). However, in more recent 
studies it has been proposed that ERp57 also on its own can recognize and bind some newly 
synthesized proteins such as MHC-I HC in the absence of calnexin and calreticulin (Zhang, 
Kozlov et al. 2009). An important function of ERp57 is its thiol-dependent reductase activity 
that catalyse the formation of protein disulide-bonds during the folding of glycoproteins in 
the ER (Tector and Salter 1995). However, in contrast, it has been shown that in the PLC and 
during the maturation of MHC-I, ERp57 has a more structural role by stabilising tapasin and 
the PLC (Garbi, Tanaka et al. 2006). The heterodimer of tapasin and ERp57 has also been 
shown to have a peptide editing function thereby playing a key role in the generation of 
mature and stable pMHC-I complexes that are to be presented on the cell surface (Wearsch 
and Cresswell 2007). 
An ubiquitous deletion of the ERp57 gene in mouse results in death in utero. To study the 
effects of ERp57 deficiency this problem was circumvented by generating a tissue specific 
deletion in the B cell compartment that resulted in B cells lacking the expression of ERp57 
(Garbi, Tanaka et al. 2006). The development and survival of the ERp57 deficient B cells 
were not affected nor was there any indication that the folding of glycoproteins such as the 
immunoglobulin, CD25, CD1d, CD19, CD23, CD72, CD40, CD80 and CD86 was reduced. 
This suggests that ERp57 is not essential for the basic B cell functions and glycoprotein 
folding in these mouse cells (Garbi, Tanaka et al. 2006). However, in another study the 
folding of specific glycoprotein substrates was shown to be reduced in the absence of ERp57 
(Jessop, Chakravarthi et al. 2007). Even though the general glycoprotein folding was not 
shown to be affected in the ERp57 deficient B cells there was a significantly lower surface 
expression of MHC-I molecules (H-2Kb showing a reduction of 50% whereas H-2Db was 
only slightly reduced) compared to non-B cells expressing wild type amounts of ERp57 
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(Garbi, Tanaka et al. 2006). This further confirms the importance of ERp57 as a key player in 
generation of stable mature MHC-I molecules. 
4.3 Tapasin optimizes the MHC-I peptide repertoire by releasing only stable pMHC-I  
Tapasin (TAP associated glycoprotein) was discovered more than a decade ago and has 
during the years been assigned a central role in the loading aspects of the MHC-I quality 
control (Sadasivan, Lehner et al. 1996). In 1994, the description of the human lympho-
blastoid B-cell line, termed LCL-721.220, marked the beginning of the discovery of tapasin. 
The LCL-721.220 did not have any HLA-A or HLA-B and only minor expression of HLA-C, 
and were devoid of full-length tapasin (Copeman, Bangia et al. 1998). The HLA-I cell surface 
expression of different HLA-I transfectants was monitored and found to be dependent on 
the particular HLA-I allomorph (Greenwood, Shimizu et al. 1994). For example, HLA-A*1 
and HLA-B*8 were reduced to 21% of the expression in a normal cell having tapasin, 
whereas HLA-A*2, HLA-A*3 and HLA-B*7 were reduced. The HLA-I cell surface expression 
was restored when LCL-721.220 was fused with either LCL-721.174 or Daudi; cell lines 
having tapasin. Thus, LCL-721.220 lacked one or several unknown mechanisms responsible 
for the maturation of MHC-I (Grandea, Androlewicz et al. 1995). At the same time, a 48 kDa 
protein with a yet unknown function was shown to co-immunoprecipitate with TAP in a 
wild type cell line (Ortmann, Androlewicz et al. 1994). In 1996, this 48 kDa protein was 
named tapasin (Sadasivan, Lehner et al. 1996), and it was shown by western blot to be 
absent in LCL-721.220 possibly explaining the defect in MHC-I maturation (Copeman, 
Bangia et al. 1998). Later, expression of tapasin in LCL-721.220 restored MHC-I cell surface 
expression and confirmed this hypothesis (Ortmann, Copeman et al. 1997). At that time, the 
true identity of tapasin was not known. The following year, the cDNA of the TAP-associated 
protein corresponding to tapasin was cloned, and it was found that tapasin is a 428 amino 
acid large, type-I transmembrane glycoprotein with a short cytoplasmic tail (Li, Sjogren et 
al. 1997; Ortmann, Copeman et al. 1997). 
In 1997, it was proposed that tapasin is a member of the Ig superfamily containing an IgC1-
SET domain (Ortmann, Copeman et al. 1997; Herberg, Sgouros et al. 1998). Subsequently, it 
was suggested that amino acids 284 - 401 mostly originating from exon 5 has an Ig-like 
structure (Mayer and Klein 2001). This was further elaborated on using homology modeling 
suggesting that 287 - 401 has an Ig-like fold (Turnquist, Petersen et al. 2004). After many 
crystallization attempts, the first protein crystal structure was reported of tapasin in a stable 
disulfide conjugate with ERp57 (Dong, Wearsch et al. 2009). ERp57 has been proposed to 
stabilize tapasin when covalently associated through a disulfide bond (Peaper, Wearsch et 
al. 2005). The structure reveals that tapasin has two ER luminal domains. Domain-1 is the N-
terminal domain spanning residues 1-269, and domain-2 spans the remaining residues 270-
381 in the luminal part of tapasin. 
To this date, it has not been possible to predict the structure of tapasin based on the amino 
acid sequence. This could be attributed to the fact that tapasin has a unique amino acid 
sequence especially within the now recognized domain-1. Related to the unique amino acid 
sequence the structure of tapasin domain-1 also has a unique 3-dimensional fold compared 
to other proteins. This domain consists mainly of anti-parallel beta-sheets. Interestingly, 
there are several ways to describe the structure of this domain. The most obvious regions 
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within this domain are two beta-barrel-like structures that are tightly bound to each other. 
The stretch spanning the residues 77-102 contains a small alpha-helix (residues 83-90), but 
does not otherwise contain any secondary structure elements. The stretch contains the 
cysteine at position 95 and might serve as an extension from tapasin towards ERp57.  
4.3.1 Tapasin only integrates 2m-associated MHC-I HC into the PLC 
Tapasin directly interacts with at least three components inside the PLC; it bridges MHC-I 
and TAP, and is simultaneously covalently bound to ERp57 thereby serving as an important 
structural component in the PLC. Tapasin does only interact with 2m-associated MHC-I 
HC supported by observations showing that the MHC-I HC cannot be co-
immunoprecipitated together with tapasin in Daudi cells, a 2m negative cell line (Paulsson, 
Wang et al. 2001). Furthermore, the PLC is not assembled in Daudi cells, strongly suggesting 
that the MHC-I maturation takes place in successive stages inside the ER, and that 2m is 
required for interaction with tapasin and integration into the PLC (Lewis and Elliott 1998). A 
contrasting study reported that tapasin directly interacts with MHC-I in the absence of 2m 
(Rizvi and Raghavan 2006). In the absence of other cellular components it was shown that 
recombinant tapasin directly interacts with MHC-I HC alone or the MHC-I heterodimer. 
The study also showed that sufficient 2m would effectively disrupt the tapasin-MHC-I 
interaction. In this regard, it may be speculated that in this in vitro system sufficient amounts 
of 2m may stabilize MHC-I to such an extent, that it is no longer unstable and is therefore 
not able to interact with tapasin. 
4.3.2 In the PLC, tapasin keeps MHC-I peptide-receptive 
Exactly how MHC-I gets loaded with (the right) peptide in the ER is controversial. MHC-I 
incorporation into the PLC is mediated by tapasin structurally bridging MHC-I and TAP (Li, 
Sjogren et al. 1997; Ortmann, Copeman et al. 1997). In addition to serving as a structural 
component in the PLC, tapasin has also been suggested to facilitate peptide loading, edit the 
MHC-I peptide cargo, retain and recycle sub-optimally loaded pMHC-I complexes 
(Grandea, Lehner et al. 1997; Paulsson, Kleijmeer et al. 2002; Zarling, Luckey et al. 2003; 
Paulsson, Jevon et al. 2006). Here, we will describe what is currently known about the role of 
tapasin in MHC-I quality control within the PLC. 
To describe the chaperone and peptide-editor function of tapasin it is necessary to 
accurately define these terms. A chaperone is a protein that assists the folding of a target 
protein. Regarding tapasin, the only target protein identified is MHC-I, and the chaperone 
function of tapasin is to facilitate the folding of MHC-I. During MHC-I maturation, tapasin 
has been found to facilitate the assembly of MHC-I in the ER ultimately resulting in 
increased cell surface expression (Lauvau, Gubler et al. 1999; Zarling, Luckey et al. 2003; 
Everett and Edidin 2007). To support this notion, a study using recombinant tapasin and 
HLA-I showed that tapasin facilitates folding of HLA-I in the absence of other PLC proteins 
(Chen and Bouvier 2007). We have recently shown that tapasin has chaperone function, and 
that at least part of this chaperone function is located within the first 87 amino acids of 
tapasin (Tpn1-87) (Roder, Geironson et al. 2009; Roder, Geironson et al. 2011). A cell-free 
assay was developed to study the Tpn1-87 chaperone function on folding HLA-I under 
controllable conditions. We observed that Tpn1-87 facilitated the folding of HLA-I, and the 
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extend of the folding could be directly, but inversely, correlated with the intrinsic stability of 
the pMHC-I complex. Based on these observations a model for the tapasin chaperone 
function can be constructed in which, tapasin chaperones the MHC-I heterodimer by 
keeping it in a peptide-receptive state. A suboptimal peptide that only confers a low-
stability pMHC-I complex will either not release bound tapasin (and thus be retained in the 
ER), or the pMHC-I will quickly disintegrate, and tapasin will instantly re-associate to the 
MHC-I heterodimer. Only optimal peptides will confer a highly stable pMHC-I complex 
and cause the release of tapasin. 
Regarding the aforementioned peptide-editor function, it is here defined as tapasin catalyzing 
the exchange of peptides on MHC-I. More specifically, tapasin directly interacts with the 
MHC-I thereby keeping it in a peptide-receptive conformational state. Only when an 
optimal peptide is loaded onto the MHC-I will tapasin release the MHC-I as shown in a 
study using recombinant proteins (Rizvi and Raghavan 2006). Tapasin and ERp57 are 
disulfide linked in the PLC, and it was shown this tapasin-ERp57 disulfide conjugate 
catalyzes MHC-I peptide-exchange (Peaper, Wearsch et al. 2005). Interestingly, both tapasin 
chaperone and peptide-editor function can be thought of as consequences of the same 
underlying tapasin mechanism, which is tapasin assisted stabilization of MHC-I. Tapasin 
arrests the MHC-I in a conformation preventing the MHC-I from aggregation and 
degradation, the chaperone function. The same conformation also keeps the MHC-I in a 
peptide-receptive state, allowing the association and dissociation of peptides. Only an 
optimal peptide binding to the MHC-I is able to change the MHC-I conformation causing 
the release of MHC-I from tapasin. Taken together, chaperone and peptide-editor functions 
of tapasin could be considered the mere consequences of its interaction with the MHC-I. 
One consequence of keeping the MHC-I in a peptide-receptive conformation is giving an 
increasing diversity of peptides a chance to bind to the MHC-I. Of course, in the ER most of 
these peptides will be of suboptimal nature. In this line of reason, tapasin is expected to alter 
the pool of peptides presented by MHC-I. This was observed in one study that reported a 
reduced number of peptides presented on HLA-A*02:01 in the absence of tapasin (Barber, 
Howarth et al. 2001). This observation supports the theory presented here, because in the 
absence of tapasin suboptimal peptides will out-compete the optimal peptide for binding to 
HLA-A*02:01, and the suboptimal pMHC-I complexes will still be transported to the cell 
surface, because tapasin is not present to retain them in the ER.  
4.3.3 Tapasin mediates recycling of unstable pMHC-I back to the ER 
Assurance of mature and highly stable pMHC-I complexes on the cell surface in wild-type 
cells has generally been attributed to ER retention of immature MHC-I. The established theory 
arises from different experimental systems showing that tapasin retains MHC-I molecules in 
the ER until loaded with optimal peptides, i.e. peptides binding to MHC-I and resulting in 
stable pMHC-I complexes (Schoenhals, Krishna et al. 1999; Grandea, Golovina et al. 2000). 
In addition, a recycling mechanism of MHC-I from late secretory compartments back to the 
ER has been suggested to exist based on evidence from several studies (Hsu, Yuan et al. 1991; 
Bresnahan, Barber et al. 1997; Park, Lee et al. 2001; Paulsson, Kleijmeer et al. 2002). Shown in 
figure 2 are COP-I coated vesicles that recognize and bind to C-terminal KKXX-motifs in 
membrane proteins thereby functioning as ER retrieval signals for proteins (Cosson and 
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Letourneur 1994). The findings that tapasin contains a C-terminal KKXX-motif and has been 
shown to have prolonged association with sub-optimally loaded pMHC-I complexes led to the 
investigation of tapasin involvement in COP-I transport (Paulsson, Kleijmeer et al. 2002). 
Tapasin was demonstrated to bind to COP-I via its KKXX-motif (Paulsson, Jevon et al. 2006). 
In cells expressing tapasin with the KKXX-motif mutated to AAXX, neither tapasin nor MHC-I 
were detected in association with COP-I, indicating a direct role for the tapasin KKXX-motif in 
mediating the MHC-I transport by COP-I coated vesicles. In the same cells, cell surface 
expression of MHC-I molecules was significantly increased, but MHC-I degradation was also 
increased suggesting escape to the cell surface of immature MHC-I. Thus, immature pMHC-I 
complexes having accidentally escaped the ER before being loaded with an optimal peptide, 
can be returned to the PLC in the ER for another round of peptide cargo optimization before 
being exported to the cell surface as mature and stable pMHC-I complexes. 
4.3.4 The maturation of different MHC-I allomorphs depends differently on tapasin 
A frequently used concept in the tapasin literature is tapasin dependency associated with each 
MHC-I allomorph. There has been a lack of previous consensus of this concept, and the use 
of dependency has been used referring to several types of distinct observations. In its strict 
sense, the dependency is how the cell surface expression of MHC-I depends on the presence 
of tapasin inside the cell. Thus, cell surface expression of HLA-I allomorphs that are highly 
dependent on tapasin will then be dramatically reduced in the absence of tapasin and vice 
versa. In this sense, HLA-I antigen presentation is controlled by tapasin to an extent 
depending on the HLA-I allomorph. To further investigate this dependency, we recently 
quantified the ability of Tpn1-87 to chaperone different pMHC-I complexes, see figure 4. 
HLA-B*44:02 has been shown to be almost completely dependent on tapasin, since HLA-
B*44:02 steady-state surface expression level is reduced by more than 90% in the tapasin 
deficient LCL-721.220 human cell line compared to the transfected homologues (Peh, 
Burrows et al. 1998). The same study also showed that HLA-B*27:05 surface expression was 
only slightly dependent on tapasin, whereas HLA-B*08:01 in this and another study was 
shown to be intermediate dependent on tapasin (Zarling, Luckey et al. 2003). 
 
 
Fig. 4. MHC-I residues related to tapasin dependency (a), and tapasin chaperoning of 
different pMHC-I complexes (b). 
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Regarding the specificity of the tapasin-MHC-I interaction, several reports have shown that 
entire regions and single residues on MHC-I and tapasin that are important in their 
interaction and function. The most well-studied single mutation was in HLA-A*02:01 where 
a threonine at position 134 was mutated to a lysine (T134K) (Lewis, Neisig et al. 1996; Peace-
Brewer, Tussey et al. 1996). The HLA-A*02:01-T134K mutant allomorph is unable to interact 
with tapasin, and this mutation can thus be used as a negative control in experiments 
studying the tapasin- MHC -I interaction. 
Notoriously, it is the amino acid sequence that makes MHC-I allomorph distinct. The amino 
acid at position 114 of HLA-B*44:02 and HLA-B*27:05 has been shown to be of crucial 
importance regarding tapasin dependence, the higher the acidity of this amino acid the 
higher the tapasin dependence (Park, Lee et al. 2003). HLA-B*27:05 and HLA-B*44:02 
(D114H) both have histidine at position 114, and are both tapasin-independent, while HLA-
B*44:02 and HLA-B*35:01 have aspartic acid at residue 114 and are demonstrated to be 
dependent on tapasin (Peh, Burrows et al. 1998; Park, Lee et al. 2003). It is very interesting 
that a single residue (in certain HLA-I allomorphs) can completely change tapasin 
dependency, and it is especially interesting that residue 114 has this effect since it is not surface 
exposed, but buried deep down in the peptide binding groove close to the apex of the F-
pocket. The tapasin interaction site on MHC-I is thought to be the surface exposed loop where 
the much discussed residue 134 is situated, and thus residue 114 is distal to the proposed 
tapasin interaction site, but is even though a strong determinant of tapasin dependence. 
4.3.5 Tapasin stabilizes TAP and increases peptide transport efficiency  
Tapasin binds directly to MHC-I, and form together with TAP the core of the PLC. The TAP-
tapasin complex interacts with MHC-I, calreticulin and ERp57 to form a fully functional 
PLC capable of loading peptides into the peptide-receptive MHC-I binding groove (Garbi, 
Tan et al. 2000; Gao, Adhikari et al. 2002; Williams, Peh et al. 2002; Garbi, Tanaka et al. 2006), 
see figure 2. The precise binding site to TAP has not yet been mapped, but it has been 
suggested that the first N-terminal transmembrane helix of TAP binds to the 
transmembrane domain of tapasin (Koch, Guntrum et al. 2006), supported by the fact that 
soluble human tapasin variants are defective in TAP association, also resulting in MHC-I 
that does not bind to TAP (Sadasivan, Lehner et al. 1996). As we will go in more detail with 
in a later section, TAP transports cytosolic peptides into the ER lumen. TAP exists as a 
TAP1/2 heterodimer, which was shown to be stabilized by tapasin (Garbi, Tiwari et al. 
2003). Furthermore, tapasin was shown to increase the peptide transport throughput by 
TAP (Li, Paulsson et al. 2000). Thus, in addition to localizing MHC-I close to the source of 
peptide transportation, tapasin also structurally bridges the PLC together while at the same 
time interacts with and keeps the MHC-I in a peptide-receptive conformation. 
5. The MHC-I binding peptide has been processed by many proteases 
5.1 The proteasome generates long peptides from degradable proteins 
Large multicatalytic protease complexes named proteasomes are located in the cytosol and 
degrade proteins as part of normal cellular turnover. The proteasome is essential for MHC-I 
antigen presentation, and inhibitors of the proteasome reduce the generation of peptides 
presented on MHC-I molecules (Rock, Gramm et al. 1994). Defective ribosomal products 
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(DRiPs) are polypeptides that never reach a functional state owing to errors in translation or 
folding. They are rapidly ubiquitylated during translation and have been shown to be a 
major source of peptides presented by MHC-I (Reits, Vos et al. 2000; Schubert, Anton et al. 
2000). The use of these newly translated proteins, facilitates rapid recruitment of effector 
cells to virally infected cells, resulting in a more efficient withdrawal of the infection.    
The proteasome contains IFN--inducible subunits. Under conditions of IFN-け induction the 
1, く2 and く5 subunits are replaced by immunosubunits, low-molecular-mass polypeptide 2 
(LMP2), multi-catalytic endopeptidase complex-like 1 (MECL-1) and LMP7 respectively, 
resulting in assembly of new proteasomes called immunoproteasome (Loukissa, Cardozo et al. 
2000; Jamaluddin, Wang et al. 2001). Immunoproteasomes are concentrated around the ER, 
whereas constitutive proteasomes are distributed evenly in the cytoplasm and in the nucleus 
(Brooks, Murray et al. 2000). Immunoproteasomes, compared to constitutive proteasomes, 
have an increased capacity to cleave peptides after hydrophobic and basic residues but 
reduced capacity to cleave after acidic amino acids (Gaczynska, Rock et al. 1993; Gaczynska, 
Rock et al. 1994). Furthermore, immunoproteasomes generate peptides with an extended N-
terminal sequence that will facilitate transport into the ER (Cascio, Hilton et al. 2001; Knuehl, 
Spee et al. 2001). Even though immunoproteasomes favour the production of peptides 
presented by MHC-I molecules, they are not an absolute requirement (Arnold, Driscoll et al. 
1992; Yewdell, Lapham et al. 1994), and some antigenic peptides are even efficiently produced 
by the constitutive proteasomes only (Chapiro, Claverol et al. 2006). 
5.2 TAP transports cytosolic peptides into the ER and supports MHC-I quality control 
An essential part of the PLC is the heterodimeric TAP composed of the TAP1 and TAP2 
subunits, both containing an N-terminal transmembrane domain and a C-terminal cytosolic 
nucleotide-binding domain. TAP1 and TAP2 have 10 and 9 transmembrane helices, 
respectively, where the 6 C-terminal helices from each subunit build together to form the so 
called 6+6 TM core complex which has been shown to be essential and sufficient for ER 
targeting, assembly of the heterodimer, binding of peptide and peptide translocation (Koch, 
Guntrum et al. 2004). The translocation is a multistep process, beginning with association of 
peptides with TAP in an ATP-independent manner (Androlewicz, Anderson et al. 1993; van 
Endert, Tampe et al. 1994; Neumann and Tampe 1999). Peptides with a length of 8-16 amino 
acids are preferentially bound to TAP (van Endert, Tampe et al. 1994). Peptides with 8-12 
amino acids are transported most efficiently, although peptides longer than 40 amino acids are 
also transported, albeit with a lower efficiency (Androlewicz, Anderson et al. 1993; Koopmann, 
Post et al. 1996). The C-terminal amino acid and the first three N-terminal residues of the 
peptide have been shown to play a key role in TAP recognition (Scholz and Tampe 2005). 
Peptides with basic or hydrophobic amino acids at the C-terminus are particularly preferred 
by human TAP. Peptide binding to TAP is followed by a slow isomerization of the TAP 
complex that triggers an ATP-dependent peptide translocation across the ER membrane 
(Neefjes, Momburg et al. 1993; Shepherd, Schumacher et al. 1993; Scholz and Tampe 2005). 
5.3 Calreticulin and calnexin bind peptides – part of the peptide relay system 
As has been previously described both calnexin and calreticulin are multifunctional 
proteins. In addition to playing a key role in the maturation of MHC-I molecules via the 
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calnexin/calreticulin cycle it has also been shown that they are able to bind peptides. 
Neefjes and colleagues have shown that both the chaperones calnexin and calreticulin bind 
peptides in vitro (Spee and Neefjes 1997; Spee, Subjeck et al. 1999). Calreticulin has also been 
shown to bind peptides in vivo (Nair, Wearsch et al. 1999). Many other heat shock proteins 
have also been demonstrated to bind peptide and a model of peptide transfer along a line of 
chaperones from the cytosol to the lumen of the ER – the peptide relay system – has been 
suggested to be responsible for directing peptides towards MHC-I presentation (Srivastava, 
Udono et al. 1994). The complexes formed when chaperones bind peptide have been 
suggested to bind to heat shock protein receptors on the surface of professional APCs, 
which leads to en internalization of the complex. The peptide from the complex is then 
presented by the MHC-I resulting in the elicitation of a CTL response. It has also been 
shown that chaperone-peptide complexes can stimulate the APCs to secrete certain 
cytokines (Srivastava, Menoret et al. 1998).  
5.4 ERAP aminopeptidases trim ER peptides to fit the MHC-I peptide binding groove 
After the peptides have been transported by TAP into the ER they may be further trimmed 
by aminopeptidases such as ER aminopeptidases 1 and 2 (ERAP1 and ERAP2) (Saric, Chang 
et al. 2002; Serwold, Gonzalez et al. 2002; Saveanu, Carroll et al. 2005). Although both are 
members of the M1 family of zinc metolloproteases (Rawlings, Barrett et al. 2010) ERAP1 
and ERAP2 show striking differences in their substrate preferences. ERAP1 has a preference 
for large hydrophobic residues while ERAP2 prefers basic residues (Hattori, Kitatani et al. 
2000; Tanioka, Hattori et al. 2003; Saveanu, Carroll et al. 2005). In contrast to most other 
aminopeptidases, that are more or less restricted to cleaving peptides shorter than four 
residues, ERAP1 shows a strong increase in cleaving activity towards peptides that are 
between 10-16 residues long (York, Chang et al. 2002). As ERAP1 and ERAP2 cleave 
substrates with different preferential for the N-terminal residues ERAP1 and ERAP2 have 
been suggested to work in concert for trimming of MHC-I binding peptides (Saveanu, 
Carroll et al. 2005).  
The mechanism by with ERAP1 recognizes and cleaves peptides of a specific length has 
been debated. The crystal structure of ERAP1 (bound to bestatin) reveals a large cavity that 
would explain the preference for longer substrates compared to most other aminopeptidases 
(Nguyen, Chang et al. 2011). In this large cavity a catalytic site is found to which the N-
terminal part of the peptide binds. It has been proposed that in close proximity to this 
catalytic site a regulatory site is found to which the C-terminal part of the peptide is bound, 
this “double binding” ensures a closed conformation of the ERAP1 molecule resulting in 
effective cleaving of the peptide. However, if the peptide is too short the C-terminal will not 
reach the regulatory site and the “double binding” will not be achieved resulting in an 
ineffective cleaving of the peptide (Nguyen, Chang et al. 2011). 
The preference for longer immature antigenic peptide precursors supports the role of 
ERAP1 in the processing of antigenic peptides that are to be presented on MHC-I 
molecules, which preferentially bind peptides of eight to ten amino acid residues. It has 
been shown that over expression of ERAP1 enhances the presentation of antigenic 
peptides by MHC-I, confirming the importance of ERAP1 for MHC-I antigen presentation. 
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In agreement with this is the finding from ERAP1 siRNA knock down studies that 
showed a reduction in antigenic peptides presented by the MHC-I molecules (York, 
Chang et al. 2002). In mice ERAP1 deficiency gives a significantly reduced MHC-I 
expression on the cell surface (Yan, Parekh et al. 2006). ERAP1 is IFN- inducible as is 
many important APM components, putting ERAP1 in the same category (York, Chang et 
al. 2002). 
6. Perspectives 
Understanding the antigen processing and quality control of pMHC-I complexes is likely to 
significantly help us understand the criteria for why some MHC-I binding peptides are 
presented while others are not, and also why some peptides are able, and others are unable 
to function as CTL epitopes. The stability of pMHC-I complexes is likely to influence both 
positive and negative selection of responding CTLs implicating pMHC-I quality control as 
important in both autoimmune disease and as tumour antigens. Moreover, expression of 
many APM components is altered in many tumours and certain virus alter APM component 
activity and/or expression, and as a consequence change the MHC-I presented peptide pool 
both qualitatively and quantitatively. In conclusion further study of the APM and quality 
control of MHC-I will improve the identification of epitopes involved in both malignant 
neoplasms, viral diseases and in autoimmune diseases. 
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